ACELYRIN INC. - COMMON STOCK

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

06 يناير 2025 16:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

02 يناير 2025 20:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

10 ديسمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

13 نوفمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

06 نوفمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

16 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

19 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery

10 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

22 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

13 أغسطس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

06 أغسطس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024

05 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

29 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

09 مايو 2024 08:01:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Leadership Transition

09 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

29 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

28 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

20 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

11 مارس 2024 08:02:00 بحسب Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

11 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire